China Resources Pharma Subsidiary Concludes RMB 1.5 Billion Corporate Bond Issuance

Stock News

Apr 16

China Resources Pharma (03320) has announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holding Co., Ltd., has completed the issuance of the first tranche of its 2026 corporate bonds in China, with a total value of RMB 1.5 billion. The issuance was carried out under the approval of the China Securities Regulatory Commission (Approval No. 1457 [2025]), which granted permission for the subsidiary to issue up to RMB 10 billion in corporate bonds to qualified investors in China. The initial tranche of the 2026 corporate bonds carries a three-year term and an annual coupon rate of 1.65%. The net proceeds from the issuance will be allocated to productive expenditures, including the repayment of corporate debt, replenishment of working capital, project development and operational expenses, investments related to technological innovation, and other uses in compliance with applicable laws and regulations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1149192156"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1149192156\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1149192156?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-16 19:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149192156","market":"us","top_or_hot":-1,"title":"China Resources Pharma Subsidiary Concludes RMB 1.5 Billion Corporate Bond Issuance","media":"Stock News","content":"<p>China Resources Pharma (03320) has announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holding Co., Ltd., has completed the issuance of the first tranche of its 2026 corporate bonds in China, with a total value of RMB 1.5 billion. The issuance was carried out under the approval of the China Securities Regulatory Commission (Approval No. 1457 [2025]), which granted permission for the subsidiary to issue up to RMB 10 billion in corporate bonds to qualified investors in China. The initial tranche of the 2026 corporate bonds carries a three-year term and an annual coupon rate of 1.65%. The net proceeds from the issuance will be allocated to productive expenditures, including the repayment of corporate debt, replenishment of working capital, project development and operational expenses, investments related to technological innovation, and other uses in compliance with applicable laws and regulations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Resources Pharma Subsidiary Concludes RMB 1.5 Billion Corporate Bond Issuance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Resources Pharma Subsidiary Concludes RMB 1.5 Billion Corporate Bond Issuance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-16 19:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Resources Pharma (03320) has announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holding Co., Ltd., has completed the issuance of the first tranche of its 2026 corporate bonds in China, with a total value of RMB 1.5 billion. The issuance was carried out under the approval of the China Securities Regulatory Commission (Approval No. 1457 [2025]), which granted permission for the subsidiary to issue up to RMB 10 billion in corporate bonds to qualified investors in China. The initial tranche of the 2026 corporate bonds carries a three-year term and an annual coupon rate of 1.65%. The net proceeds from the issuance will be allocated to productive expenditures, including the repayment of corporate debt, replenishment of working capital, project development and operational expenses, investments related to technological innovation, and other uses in compliance with applicable laws and regulations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"华润医药","start_time":0,"source_url":"","article_id":"1149192156","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149192156","pubTimestamp":1776338954,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"China Resources Pharma (03320) has announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holding Co., Ltd., has completed the issuance of the first tranche of its 2026 corporate...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药","BK1570":"华润系","BK1191":"制药"},"translate_title":"华润医药子公司完成15亿元公司债发行","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"China Resources Pharma (03320) has announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holding Co., Ltd., has completed the issuance of the first tranche of its 2026 corporate bonds in China, with a total value of RMB 1.5 billion. The issuance was carried out under the approval of the China Securities Regulatory Commission (Approval No. 1457 [2025]), which granted permission for the subsidiary to issue up to RMB 10 billion in corporate bonds to qualified investors in China. The initial tranche of the 2026 corporate bonds carries a three-year term and an annual coupon rate of 1.65%. The net proceeds from the issuance will be allocated to productive expenditures, including the repayment of corporate debt, replenishment of working capital, project development and operational expenses, investments related to technological innovation, and other uses in compliance with applicable laws and regulations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}